Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
about
Six months therapy for tuberculous meningitisMortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weightingPediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenAdding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients.Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats.Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study.Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.Are the Present Doses of Anti Tubercular Drugs Adequate for Severe Disease?Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Innovative Methods to Manage, Detect, and Prevent Tuberculosis.Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Treatment of Tuberculous Meningitis and Its Complications in Adults.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes
P2860
Q28074247-72BD18AC-1634-4E23-BDBB-7631AA72A846Q31102969-617C5A33-0095-46C9-9D4E-38C15901E9E8Q35742101-68025FE3-DB28-4264-BE4D-2A3BF375045FQ35963971-E681C52C-7D9F-45AB-A541-D5F7D81F1918Q35974112-6E861E59-2671-44DA-8B22-D5BB3326A214Q35978007-14E3E624-7F54-45BE-A171-E4F4B5366F8AQ36159089-9F1FF14C-F5BF-4AB5-A704-23155DC9E641Q36166714-AD2B8CA2-2B63-4DA9-B268-7A5096C3BC3CQ36273077-03CF9CE0-62DF-4CA1-A440-92B555D443ABQ36540902-3FE0B5F1-2230-4F14-8DF0-9CE1AAA65D3FQ39062016-0F89BF78-6E1D-49F9-9BF2-117DB0D2AAFCQ39456569-C32AC3D6-F8E0-4C6C-8171-2BC2EC948584Q40444755-96EC2BD3-6E54-4510-9C59-8D564B8204EFQ47192301-0FBFEE56-30A2-41EA-8851-E0F6144E8893Q47332682-4A389B57-F59B-46C0-A7A9-0ECC35D8A70CQ52680275-7E0732D8-C67F-4D43-907C-555F2E2B1C49Q57152709-072B19C5-3AE5-4291-86D1-3E6CE052632B
P2860
Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@ast
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@en
type
label
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@ast
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@ast
Pharmacokinetic/pharmacodynami ...... in for tuberculous meningitis.
@en
P2093
P1476
Pharmacokinetic/pharmacodynami ...... cin for tuberculous meningitis
@en
P2093
Ahmad Rizal Ganiem
David Burger
Lindsey Te Brake
Reinout van Crevel
Rob Aarnoutse
Rogier Donders
Rovina Ruslami
P304
P356
10.1016/J.IJANTIMICAG.2014.12.027
P577
2015-02-07T00:00:00Z